Search
Close this search box.

SPOT ME: Serial Pediatric Omics Tracking for ME/CFS

  • Natalie Thomas, PhD
  • Tracey Chau, PhD
  • David Fineberg, MBBS, FRACGP, DCH
  • Katherine Huang
  • Elisha Josev, PhD
  • Sarah Knight, PhD
  • Adam Scheinberg, FRACP, FAFRM, MMed(ClinEpi)
  • Paul Gooley, PhD
  • Christopher Armstrong, PhD
  • Minimum target of 20 ME/CFS and 20 healthy controls have been collected.
  • Recruitment phase ends 2024.
  • Starting to conduct Omics analysis on existing samples.

STUDY HYPOTHESIS AND DESCRIPTION

Research on ME/CFS in teenagers is not very common, even though a lot of teens start showing symptoms of this disease. The goal of this research project is to collect detailed information from teenagers with ME/CFS during a single visit to a doctor. This visit will include an MRI scan, brain function tests, and collecting body fluids like blood or saliva. These samples will help scientists look at thousands of biological markers and check how well the mitochondria (energy-producing parts of cells) are working in these patients.

Additionally, the teens will get a kit to take home so they can collect more samples on their own. This will help us see what changes in their biological markers on days when they feel better compared to days when they feel worse.

This focus on teenagers is important because their ME/CFS often starts after the same kind of trigger, such as an infection by the EBV virus, and they are usually diagnosed early in the course of their illness. They also tend to have fewer other health issues compared to adults with ME/CFS. Understanding ME/CFS in teens is crucial because the disease can greatly affect their social life, schooling, and future job opportunities, not to mention the strain it puts on their families.

OBJECTIVES

A woman physician takes notes as a patient tilts her head and points to her throat.

  1. Deeply profile the biology of pediatric ME/CFS patients vs controls.
  2. Test cellular energy metabolism changes in ME/CFS vs controls.
  3. Evaluate “good day” signatures vs “bad day” signatures in pediatric ME/CFS.
  4. Assess biology for patterns that corresponds to patient symptoms in individuals.
  5. Cluster patients based on similar biology-symptom dynamics.